Pacira Pharmaceuticals

Pacira Pharmaceuticals

Pacira Pharmaceuticals was founded in 1985 as a specialty pharmaceutical company, but its modern identity was shaped under David Stack, who took over as CEO in 2008. The wealth origin is corporate — the firm is publicly traded on the NASDAQ under the ticker PCRX. Stack shifted the focus to non-opioid pain management, a strategic bet that paid off with the FDA approval of Exparel (bupivacaine liposome injectable suspension) in 2011. Pacira's strategy mixes internal R&D with acquisitions and commercial partnerships. Asset classes include branded pharmaceuticals, drug-device combination products, and a pipeline of candidates targeting post-surgical and acute pain. Exparel accounted for roughly 90% of 2023 revenue (per SEC filings, 2023). Geographic footprint is predominantly US-based, with some international licensing deals in Canada and Europe. Confirmed partners include Vertex Pharmaceuticals for joint research and third-party manufacturers for supply chain. As of 2025, Pacira employs around 1,200 people, per public disclosures. The firm operates no adjacent vehicles like a foundation or VC arm. Recent activity: October 2024: Announced FDA approval of a new formulation of Exparel for nerve blocks (per Pacira press release, October 2024). Pacira's structural differentiator is its singular focus on opioid-sparing therapies, which positions it at the center of a regulatory and public health push against opioid overprescription. The company holds over 100 patents protecting its liposomal drug delivery technology, creating a moat around its lead product until at least 2029.